Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relatives Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

NCT05303220
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Branebrutinib, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

NCT05525910
View directory record Official record
Conditions
Biological Availability, Healthy Participants
Interventions
Nirmatrelvir/ ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Different Formulations of LY3074828 in Healthy Participants

NCT03188510
View directory record Official record
Conditions
Healthy
Interventions
LY3074828
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

NCT01155713
View directory record Official record
Conditions
Neoplasm, Cancer, Tumors
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Scottsdale, Arizona • Durham, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Relative Bioavailability Study

NCT01098513
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1349572 formulation AP, GSK1349572 formulation AW, GSK1349572 formulation AX
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects

NCT01100060
View directory record Official record
Conditions
Malaria Prophylaxis
Interventions
azithromycin (AZ) microsphere, test chloroquine (CQ) formulation, azithromycin (AZ), chloroquine (CQ)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Jul 22, 2026, 6:40 PM EDT
Withdrawn Phase 2 Interventional

Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)

NCT02702960
View directory record Official record
Conditions
Fibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma (Fibrolamellar Variant), Hepatocellular Carcinoma
Interventions
living related donor partial liver transplantation, Total body irradiation, Bone marrow transplant from same donor, Cyclophosphamide, Mesna, Filgrastim, Tacrolimus, mycophenolate mofetil, Prednisone, Antithymocyte globulin, fludarabine
Procedure · Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
16 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting

NCT00834197
View directory record Official record
Conditions
Healthy
Interventions
Mirtazapine 15 mg (Orally Disintegrating) Tablets, REMERON SolTab® 15 mg Orally Disintegrating Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients

NCT00815750
View directory record Official record
Conditions
Prostate Cancer
Interventions
Information Gathering, Decision Aid
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability

NCT01682408
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed, Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A), Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B), Ranitidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

NCT03586843
View directory record Official record
Conditions
Obesity
Interventions
JNJ-64565111
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions

NCT01149486
View directory record Official record
Conditions
Healthy
Interventions
Losartan potassium/Hydrochlorothiazide, Hyzaar®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Entrainment Between Clinician and Patient During Palpation

NCT03579238
View directory record Official record
Conditions
Doctor Patient Relation
Interventions
CV4, touching
Procedure
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants

NCT06268860
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab vial injection, Rocatinlimab prefilled syringe
Drug · Combination Product
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions

NCT00835276
View directory record Official record
Conditions
Healthy
Interventions
Fexofenadine 180 mg tablets, ALLEGRA® 180 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.

NCT00416468
View directory record Official record
Conditions
Healthy
Interventions
Aliskiren, Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 21, 2007 · Synced Jul 22, 2026, 6:40 PM EDT
Active, not recruiting Not applicable Interventional

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

NCT03115333
View directory record Official record
Conditions
Gliosarcoma, Recurrent Glioblastoma
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Castro Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Completed No phase listed Observational

Markers for Breast Cancer

NCT00339248
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older · Female only
Enrollment
2,632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Jul 22, 2026, 6:40 PM EDT
Terminated Phase 2 Interventional Results available

A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

NCT02509585
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
Tc99m tilmanocept
Drug
Lead sponsor
Cardinal Health 414, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
La Jolla, California • Miami, Florida • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2019 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation

NCT01406158
View directory record Official record
Conditions
Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers
Interventions
Solifenacin Succinate Formulation A, Solifenacin Succinate Formulation B, Solifenacin Succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Jul 22, 2026, 6:40 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

NCT01489319
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Salsalate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jul 22, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Stereotype Threat on Impulsivity and Its Relation to Alcohol Use in African Americans: An fMRI Study

NCT05675332
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Task-based behavioral intervention
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 35 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations

NCT01979484
View directory record Official record
Conditions
Pharmacokinetic Assessments in Healthy Volunteers
Interventions
PPI-668 capsule, PPI-668 tablet
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

NCT05351892
View directory record Official record
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions
Elinzanetant (BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Jul 22, 2026, 6:40 PM EDT